stockrow
Saturday 7 November 2026
Export PPCB’s income statement to Excel — free account
Propanc Biopharma Inc
PPCB Healthcare Biotechnology
- EPS
- −99.6%
- Free cash flow
- −1,637.4%
- Total debt
- −21.4%
Quarter to June 2026, against a year earlier
1.79
0.15
+9.15%
Follow PPCB
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Trend | 10 yrs | 2027e | 2028e | 2029e | Next 3/yr |
| Income, $m | |||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | (8) | (7) | (6) | (5) | (2) | (3) | (3) | (2) | (59) | (19) | +9.7% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | (8) | (7) | (6) | (5) | (2) | (3) | (3) | (2) | (59) | (19) | +10.2% | ||||||
| Per share, $ | |||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (2.24) | (178.74) | (10.97) | (192.45) | (0.80) | (49.23) | (1.80) | (35,324.35) | (3,712.24) | (167.86) | +61.5% | ||||||
| Cash flow | (0.58) | (55.27) | (3.92) | (75.19) | (0.38) | (21.06) | (0.64) | 0.00 | (25.48) | (50.56) | +64.1% | ||||||
| Capex | 0.00 | 0.00 | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.04) | n/m | ||||||
| Free cash flow | (0.58) | (55.27) | (3.93) | (75.19) | (0.38) | (21.06) | (0.64) | 0.00 | (25.48) | (50.60) | +64.2% | ||||||
| Book value | (1.55) | (171.37) | (8.19) | (148.02) | (1.01) | (44.33) | (1.79) | 0.00 | 874.60 | 83.65 | n/m | ||||||
| Shares, m | 4 | 0 | 1 | 0 | 3 | 0 | 2 | 0 | 0 | 0 | (31.8%) | ||||||
| Valuation, × | |||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Cash, $m | |||||||||||||||||
| Cash, $m | Operating cash flow | (2) | (2) | (2) | (2) | (1) | (1) | (1) | (1) | 0 | (6) | +12.0% | |||||
| Capex | — | — | 0 | — | — | — | — | — | — | 0 | +7.8% | ||||||
| Free cash flow | (2) | (2) | (2) | (2) | (1) | (1) | (1) | (1) | 0 | (6) | +12.0% | ||||||
| Balance, $m | |||||||||||||||||
| Balance, $m | Working capital | (5) | (7) | (4) | (4) | (3) | (3) | (3) | (4) | 3 | 5 | n/m | |||||
| Net debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | +49.6% | ||||||
| Shareholders’ equity | (5) | (7) | (4) | (4) | (3) | (3) | (3) | (4) | 14 | 9 | n/m | ||||||
| Returns, % | |||||||||||||||||
| Returns, % | ROA | (3,318.22) | (8,455.50) | (6,653.26) | (4,735.96) | (4,332.80) | (7,085.23) | (4,403.94) | (3,034.66) | (598.08) | (122.15) | +3,196.1 pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (247.22) | (125.86) | (125.9) pt | ||||||
| ROE | 196.27 | 115.36 | 104.10 | 119.22 | 71.97 | 110.09 | 101.75 | 58.39 | (1,163.68) | (169.86) | (366.1) pt | ||||||
| People | |||||||||||||||||
| People | Employees | 2 | 2 | 3 | 3 | 2 | 3 | 2 | 2 | 2 | 2 | 0.0% | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 2 Nov 2026
Propanc Biopharma Inc vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| GNPX GENPREX | $1.7M | — (loss-making) | — | — | n/m | −32.98% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| PPCB Propanc Biopharma Inc | $1.7M | — (loss-making) | — | — | −99.64% (below 0%: shrinking) | −1,637.42% (below 0%: shrinking) | — | 0.00% | |
| XRTX XORTX Therapeutics Inc. | $1.7M | — (loss-making) | — | — | n/m | −318.40% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| GOVX GeoVax Labs Inc. | $1.6M | — (loss-making) | — (loss-making) | +183.44% (above 0%: growing) | n/m | +15.81% (above 0%: growing) | 100.00% | 0.00% | Compare |
| ITRMF Iterum Therapeutics PLC | $1.6M | — (loss-making) | — (loss-making) | +110.81% (above 0%: growing) | n/m | −179.15% (below 0%: shrinking) | 94.87% | (1,982.31%) | Compare |
| OGEN Oragenics, Inc. | $1.6M | — (loss-making) | — (loss-making) | −75.33% (below 0%: shrinking) | n/m | −66.37% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| VRAX Virax Biolabs Group Limited | $1.6M | — (loss-making) | — (loss-making) | — | −855.56% (below 0%: shrinking) | +32.24% (above 0%: growing) | (53.57%) | 0.00% | Compare |
| KAPA Kairos Pharma, Ltd. | $1.5M | — (loss-making) | — | — | n/m | −25.71% (below 0%: shrinking) | — | 0.00% | Compare |
| CARM Carisma Therapeutics Inc. | $1.5M | — (loss-making) | — (loss-making) | +392.01% (above 0%: growing) | n/m | +114.65% (above 0%: growing) | 100.00% | 96.83% | Compare |
| Median of peers | $1.6M | — | — | +147.13% | — | −29.34% | 94.87% | 0.00% |